Identification of critical paraoxonase 1 residues involved in high density lipoprotein interaction

Journal of Biological Chemistry

Volumn 291, Issue 4, 2016, Pages 1890-1904

  Gu, Xiaodong ^a   Huang, Ying ^a   Levison, Bruce S ^a   Gerstenecker, Gary ^b   DiDonato, Anthony J ^a   Hazen, Leah B ^a   Lee, Joonsue ^a   Gogonea, Valentin ^a,b   DiDonato, Joseph A ^a   Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINS; CATALYST ACTIVITY; CHROMATOGRAPHY; CROSSLINKING; CRYSTAL STRUCTURE; CYTOLOGY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHOSPHOLIPIDS; PROBES; PROTEINS;

COVALENT CROSS-LINKS; HIGH DENSITY LIPOPROTEIN; HIGH-DENSITY LIPOPROTEINS; IDENTIFICATION OF PROTEINS; PHOSPHOLIPID SURFACES; PROTEIN INTERACTION; SITE-SPECIFIC MUTAGENESIS; TANDEM MASS SPECTROMETRY;

LIPOPROTEINS;

AMINO ACID; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; LEUCINE; TYROSINE; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN; PROTEIN BINDING;

AFFINITY CHROMATOGRAPHY; ARTICLE; CLICK CHEMISTRY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LOCALIZATION; ENZYME STABILITY; ENZYME STRUCTURE; LIPID MEMBRANE; LIQUID CHROMATOGRAPHY; MOLECULAR DOCKING; MOLECULAR PROBE; PHOTOACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; TANDEM MASS SPECTROMETRY; CATALYSIS; CHEMISTRY; GENETICS; HUMAN; METABOLISM; PROTEIN MOTIF; X RAY CRYSTALLOGRAPHY;

AMINO ACID MOTIFS; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; CATALYSIS; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIPOPROTEINS, HDL; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING;

EID: 84959010200     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.678334     Document Type: Article

References (89)

1. Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., and Dawber, T. R. (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62, 707-714
2. Fisher, E. A., Feig, J. E., Hewing, B., Hazen, S. L., and Smith, J. D. (2012) High density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 32, 2813-2820
3. Rosenson, R. S., Brewer, H. B., Jr., Ansell, B., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., and Webb, N. R. (2013) Translation of high density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 128, 1256-1267
4. Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Sr., Davidson, M. H., Davidson, W. S., Heinecke, J. W., Karas, R. H., Kontush, A., Krauss, R. M., Miller, M., and Rader, D. J. (2013) High density lipoproteins: a consensus statement from the National Lipid Association. J. Clin. Lipidol. 7, 484-525
5. Rye, K. A., and Barter, P. J. (2014) Regulation of high density lipoprotein metabolism. Circ. Res. 114, 143-156
6. Kontush, A., Lindahl, M., Lhomme, M., Calabresi, L., Chapman, M. J., and Davidson, W. S. (2015) Structure of HDL: particle subclasses and molecular components. Handb. Exp. Pharmacol. 224, 3-51
7. Rosenson, R. S., Brewer, H. B., Jr., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X. C., Phillips, M. C., Rader, D. J., Remaley, A. T., Rothblat, G. H., Tall, A. R., and Yvan-Charvet, L. (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125, 1905-1919
8. Rader, D. J., and Hovingh, G. K. (2014) HDL and cardiovascular disease. Lancet 384, 618-625
9. Vickers, K. C., and Remaley, A. T. (2014) HDL and cholesterol: life after the divorce? J. Lipid Res. 55, 4-12
10. Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., Mueller, M., Akhmedov, A., Daniil, G., Manes, C., Templin, C., et al. (2011) Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 121, 2693-2708
11. Sorci-Thomas, M. G., and Thomas, M. J. (2012) High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler. Thromb. Vasc. Biol. 32, 2561-2565
12. Bhattacharyya, T., Nicholls, S. J., Topol, E. J., Zhang, R., Yang, X., Schmitt, D., Fu, X., Shao, M., Brennan, D. M., Ellis, S. G., Brennan, M. L., Allayee, H., Lusis, A. J., and Hazen, S. L. (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299, 1265-1276
13. Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., and Remaley, A. T. (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high density lipoproteins. Nat. Cell Biol. 13, 423-433
14. Zamanian-Daryoush, M., Lindner, D., Tallant, T. C., Wang, Z., Buffa, J., Klipfell, E., Parker, Y., Hatala, D., Parsons-Wingerter, P., Rayman, P., Yusufishaq, M. S., Fisher, E. A., Smith, J. D., Finke, J., DiDonato, J. A., and Hazen, S. L. (2013) The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J. Biol. Chem. 288, 21237-21252
15. Tabet, F., Vickers, K. C., Cuesta Torres, L. F., Wiese, C. B., Shoucri, B. M., Lambert, G., Catherinet, C., Prado-Lourenco, L., Levin, M. G., Thacker, S., Sethupathy, P., Barter, P. J., Remaley, A. T., and Rye, K. A. (2014) HDLtransferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat. Commun. 5, 3292
16. Sag, D., Cekic, C., Wu, R., Linden, J., and Hedrick, C. C. (2015) The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity. Nat. Commun. 6, 6354
17. Karlsson, H., Leanderson, P., Tagesson, C., and Lindahl, M. (2005) Lipoproteomics II: mapping of proteins in high density lipoprotein using twodimensional gel electrophoresis and mass spectrometry. Proteomics 5, 1431-1445
18. Heller, M., Stalder, D., Schlappritzi, E., Hayn, G., Matter, U., and Haeberli, A. (2005) Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics 5, 2619-2630
19. Hortin, G. L., Shen, R. F., Martin, B. M., and Remaley, A. T. (2006) Diverse range of small peptides associated with high density lipoprotein. Biochem. Biophys. Res. Commun. 340, 909-915
20. Rezaee, F., Casetta, B., Levels, J. H., Speijer, D., and Meijers, J. C. (2006) Proteomic analysis of high density lipoprotein. Proteomics 6, 721-730
21. Ståhlman, M., Davidsson, P., Kanmert, I., Rosengren, B., Borén, J., Fagerberg, B., and Camejo, G. (2008) Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J. Lipid Res. 49, 481-490
22. Li, H., Gordon, S. M., Zhu, X., Deng, J., Swertfeger, D. K., Davidson, W. S., and Lu, L. J. (2015) Network-based analysis on orthogonal separation of human plasma uncovers distinct high density lipoprotein complexes. J. Proteome Res. 14, 3082-3094
23. Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., Chea, H., Knopp, R. H., Brunzell, J., Geary, R., Chait, A., et al. (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117, 746-756
24. Davidson, W. S., Silva, R. A., Chantepie, S., Lagor, W. R., Chapman, M. J., and Kontush, A. (2009) Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29, 870-876
25. Alwaili, K., Bailey, D., Awan, Z., Bailey, S. D., Ruel, I., Hafiane, A., Krimbou, L., Laboissiere, S., and Genest, J. (2012) The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim. Biophys. Acta 1821, 405-415
26. Gordon, S. M., Deng, J., Lu, L. J., and Davidson, W. S. (2010) Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J. Proteome Res. 9, 5239-5249
27. Shah, A. S., Tan, L., Long, J. L., and Davidson, W. S. (2013) Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 54, 2575-2585
28. Birner-Gruenberger, R., Schittmayer, M., Holzer, M., and Marsche, G. (2014) Understanding high density lipoprotein function in disease: recent advances in proteomics unravel the complexity of its composition and biology. Prog. Lipid Res. 56, 36-46
29. Chang, C. T., Yang, C. Y., Tsai, F. J., Lin, S. Y., and Chen, C. J. (2015) Mass spectrometry-based proteomic study makes high density lipoprotein a biomarker for atherosclerotic vascular disease. Biomed. Res. Int. 2015, 164846
30. Shih, D. M., Gu, L., Hama, S., Xia, Y. R., Navab, M., Fogelman, A. M., and Lusis, A. J. (1996) Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97, 1630-1639
31. Huang, Y., Wu, Z., Riwanto, M., Gao, S., Levison, B. S., Gu, X., Fu, X., Wagner, M. A., Besler, C., Gerstenecker, G., Zhang, R., Li, X. M., Didonato, A. J., Gogonea, V., Tang, W. H., et al. (2013) Myeloperoxidase, paraoxonase- 1, and HDL form a functional ternary complex. J. Clin. Invest. 123, 3815-3828
32. Mackness, M. I., Arrol, S., and Durrington, P. N. (1991) Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett. 286, 152-154
33. Watson, A. D., Berliner, J. A., Hama, S. Y., La Du, B. N., Faull, K. F., Fogelman, A. M., and Navab, M. (1995) Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96, 2882-2891
34. Aviram, M., Rosenblat, M., Bisgaier, C. L., Newton, R. S., Primo-Parmo, S. L., and La Du, B. N. (1998) Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101, 1581-1590
35. Mackness, M., and Mackness, B. (2015) Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene 567, 12-21
36. Shih, D. M., Gu, L., Xia, Y. R., Navab, M., Li, W. F., Hama, S., Castellani, L. W., Furlong, C. E., Costa, L. G., Fogelman, A. M., and Lusis, A. J. (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284-287
37. Tward, A., Xia, Y. R., Wang, X. P., Shi, Y. S., Park, C., Castellani, L. W., Lusis, A. J., and Shih, D. M. (2002) Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106, 484-490
38. Tang, W. H., Wu, Y., Mann, S., Pepoy, M., Shrestha, K., Borowski, A. G., and Hazen, S. L. (2011) Diminished antioxidant activity of high density lipoprotein-associated proteins in systolic heart failure. Circ. Heart Fail. 4, 59-64
39. Tang, W. H., Hartiala, J., Fan, Y., Wu, Y., Stewart, A. F., Erdmann, J., Kathiresan, S., CARDIoGRAM Consortium, Roberts, R., McPherson, R., Allayee, H., and Hazen, S. L. (2012) Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 32, 2803-2812
40. Zhao, Y., Ma, Y., Fang, Y., Liu, L., Wu, S., Fu, D., and Wang, X. (2012) Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies. Mol. Genet. Metab. 105, 141-148
41. Kennedy, D. J., Tang, W. H., Fan, Y., Wu, Y., Mann, S., Pepoy, M., and Hazen, S. L. (2013) Diminished antioxidant activity of high density lipoprotein- associated proteins in chronic kidney disease. J. Am. Heart Assoc. 2, e000104
42. Schmitt, D., Shen, Z., Zhang, R., Colles, S. M., Wu, W., Salomon, R. G., Chen, Y., Chisolm, G. M., and Hazen, S. L. (1999) Leukocytes utilize myeloperoxidase- generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum. Biochemistry 38, 16904-16915
43. Zhang, R., Shen, Z., Nauseef, W. M., and Hazen, S. L. (2002) Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase-deficient subjects: systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma. Blood 99, 1802-1810
44. Brennan, M. L., Penn, M. S., Van Lente, F., Nambi, V., Shishehbor, M. H., Aviles, R. J., Goormastic, M., Pepoy, M. L., McErlean, E. S., Topol, E. J., Nissen, S. E., and Hazen, S. L. (2003) Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349, 1595-1604
45. Hazen, S. L. (2004) Myeloperoxidase and plaque vulnerability. Arterioscler. Thromb. Vasc. Biol. 24, 1143-1146
46. Kalantar-Zadeh, K., Brennan, M. L., and Hazen, S. L. (2006) Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am. J. Kidney Dis. 48, 59-68
47. Nicholls, S. J., and Hazen, S. L. (2009) Myeloperoxidase, modified lipoproteins, and atherogenesis. J. Lipid Res. 50, S346-S351
48. Huang, Y., DiDonato, J. A., Levison, B. S., Schmitt, D., Li, L., Wu, Y., Buffa, J., Kim, T., Gerstenecker, G. S., Gu, X., Kadiyala, C. S., Wang, Z., Culley, M. K., Hazen, J. E., Didonato, A. J., et al. (2014) An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 20, 193-203
49. Zheng, L., Nukuna, B., Brennan, M. L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., Ischiropoulos, H., Smith, J. D., Kinter, M., and Hazen, S. L. (2004) Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114, 529-541
50. Still, W. C., Kahn, M., and Mitra, A. (1978) Rapid chromatographic technique for preparative separations with moderate resolution. J. Org. Chem. 43, 2923-2925
51. Markwell, M. A., Haas, S. M., Bieber, L. L., and Tolbert, N. E. (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87, 206-210
52. Church, R. F., and Weiss, M. J. (1970) Diazirines. 11. synthesis and properties of small functionalized Diazirine molecules. Some observations on the reaction of a Diaziridine with the iodine-iodide ion system. J. Org. Chem. 35, 2465-2471
53. Schmitz, E., and Ohme, R. (1965) 3, 3-Pentamethylenediazirine. Organic Syntheses Collective Volume 5, 83
54. Bligh, E. G., and Dyer, W. J. (1959) A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911-917
55. Havel, R. J., Eder, H. A., and Bragdon, J. H. (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34, 1345-1353
56. Osborne, J. C., Jr. (1986) Delipidation of plasma lipoproteins. Methods Enzymol. 128, 213-222
57. Rye, K. A., Garrety, K. H., and Barter, P. J. (1992) Changes in the size of reconstituted high density lipoproteins during incubation with cholesteryl ester transfer protein: the role of apolipoproteins. J. Lipid Res. 33, 215-224
58. Matz, C. E., and Jonas, A. (1982) Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J. Biol. Chem. 257, 4535-4540
59. Baker, P. W., Rye, K. A., Gamble, J. R., Vadas, M. A., and Barter, P. J. (2000) Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J. Lipid Res. 41, 1261-1267
60. Aharoni, A., Gaidukov, L., Yagur, S., Toker, L., Silman, I., and Tawfik, D. S. (2004) Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. U.S.A. 101, 482-487
61. Hannoush, R. N., and Arenas-Ramirez, N. (2009) Imaging the lipidome: omega-alkynyl fatty acids for detection and cellular visualization of lipidmodified proteins. ACS Chem. Biol. 4, 581-587
62. Weerapana, E., Speers, A. E., and Cravatt, B. F. (2007) Tandem orthogonal proteolysis-activity-based protein profiling (TOP-ABPP)-a general method for mapping sites of probe modification in proteomes. Nat. Protoc. 2, 1414-1425
63. Speers, A. E., and Cravatt, B. F. (2005) A tandem orthogonal proteolysis strategy for high content chemical proteomics. J. Am. Chem. Soc. 127, 10018-10019
64. Eng, J. K., McCormack, A. L., and Yates, J. R. (1994) An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5, 976-989
65. Tabb, D. L., McDonald, W. H., and Yates, J. R., 3rd. (2002) DTASelect and Contrast: tools for assembling and comparing protein identifications from shotgun proteomics. J. Proteome Res. 1, 21-26
66. Das, J. (2011) Aliphatic diazirines as photoaffinity probes for proteins: recent developments. Chem. Rev. 111, 4405-4417
67. Rostovtsev, V. V., Green, L. G., Fokin, V. V., and Sharpless, K. B. (2002) A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem. Int. Ed. Engl. 41, 2596-2599
68. Best, M. D., Rowland, M. M., and Bostic, H. E. (2011) Exploiting bioorthogonal chemistry to elucidate protein-lipid binding interactions and other biological roles of phospholipids. Acc. Chem. Res. 44, 686-698
69. Pajouhesh, H., and Hancock, A. J. (1983) Synthesis of conformationally restricted acidic lipids. I. Cyclopentanoid analogs of phosphatidylserine. J. Lipid Res. 24, 645-651
70. Menashe, M., Romero, G., Biltonen, R. L., and Lichtenberg, D. (1986) Hydrolysis of dipalmitoylphosphatidylcholine small unilamellar vesicles by porcine pancreatic phospholipase A2. J. Biol. Chem. 261, 5328-5333
71. Gu, X., Zhang, W., Choi, J., Li, W., Chen, X., Laird, J. M., and Salomon, R. G. (2011) An (1)O2 route to gamma-hydroxyalkenal phospholipids by vitamin E-induced fragmentation of hydroperoxydiene-derived endoperoxides. Chem. Res. Toxicol. 24, 1080-1093
72. Hulce, J. J., Cognetta, A. B., Niphakis, M. J., Tully, S. E., and Cravatt, B. F. (2013) Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells. Nat. Methods 10, 259-264
73. Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R. B., McCarthy, A., Toker, L., Silman, I., Sussman, J. L., and Tawfik, D. S. (2004) Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11, 412-419
74. Noto, H., Hashimoto, Y., Satoh, H., Hara, M., Iso-o, N., Togo, M., Kimura, S., and Tsukamoto, K. (2001) Exclusive association of paraoxonase 1 with high density lipoprotein particles in apolipoprotein A-I deficiency. Biochem. Biophys. Res. Commun. 289, 395-401
75. Josse, D., Ebel, C., Stroebel, D., Fontaine, A., Borges, F., Echalier, A., Baud, D., Renault, F., Le Maire, M., Chabrieres, E., and Masson, P. (2002) Oligomeric states of the detergent-solubilized human serum paraoxonase (PON1). J. Biol. Chem. 277, 33386-33397
76. Kuo, C. L., and La Du, B. N. (1995) Comparison of purified human and rabbit serum paraoxonases. Drug Metab. Dispos. 23, 935-944
77. Gaidukov, L., and Tawfik, D. S. (2005) High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44, 11843-11854
78. Wu, Z., Gogonea, V., Lee, X., Wagner, M. A., Li, X. M., Huang, Y., Undurti, A., May, R. P., Haertlein, M., Moulin, M., Gutsche, I., Zaccai, G., Didonato, J. A., and Hazen, S. L. (2009) Double superhelix model of high density lipoprotein. J. Biol. Chem. 284, 36605-36619
79. Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D., and Rosenblat, M. (2000) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase- like activities. Circulation 101, 2510-2517
80. Stevens, R. C., Suzuki, S. M., Cole, T. B., Park, S. S., Richter, R. J., and Furlong, C. E. (2008) Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc. Natl. Acad. Sci. U.S.A. 105, 12780-12784
81. Gaidukov, L., Bar, D., Yacobson, S., Naftali, E., Kaufman, O., Tabakman, R., Tawfik, D. S., and Levy-Nissenbaum, E. (2009) In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes. BMC Clin. Pharmacol. 9, 18
82. Rochu, D., Chabrière, E., and Masson, P. (2007) Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 233, 47-59
83. Valiyaveettil, M., Alamneh, Y. A., Doctor, B. P., and Nambiar, M. P. (2012) Crossroads in the evaluation of paraoxonase 1 for protection against nerve agent and organophosphate toxicity. Toxicol. Lett. 210, 87-94
84. Zhang, R., Brennan, M. L., Shen, Z., MacPherson, J. C., Schmitt, D., Molenda, C. E., and Hazen, S. L. (2002) Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J. Biol. Chem. 277, 46116-46122
85. Podrez, E. A., Febbraio, M., Sheibani, N., Schmitt, D., Silverstein, R. L., Hajjar, D. P., Cohen, P. A., Frazier, W. A., Hoff, H. F., and Hazen, S. L. (2000) Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest. 105, 1095-1108
86. Brennan, M. L., Wu, W., Fu, X., Shen, Z., Song, W., Frost, H., Vadseth, C., Narine, L., Lenkiewicz, E., Borchers, M. T., Lusis, A. J., Lee, J. J., Lee, N. A., Abu-Soud, H. M., Ischiropoulos, H., and Hazen, S. L. (2002) A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J. Biol. Chem. 277, 17415-17427
87. Wang, Z., Nicholls, S. J., Rodriguez, E. R., Kummu, O., Hörkkö, S., Barnard, J., Reynolds, W. F., Topol, E. J., DiDonato, J. A., and Hazen, S. L. (2007) Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 13, 1176-1184
88. Khersonsky, O., and Tawfik, D. S. (2006) The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J. Biol. Chem. 281, 7649-7656
89. Rosenblat, M., Gaidukov, L., Khersonsky, O., Vaya, J., Oren, R., Tawfik, D. S., and Aviram, M. (2006) The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281, 7657-7665